Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416884 | 0.84 | ALDH1A1 (0.41) | ALDH1A1MAPK1MTNR1AMTNR1BFFAR1 | |
| SCHEMBL670441 | 0.75 | LIPE (0.35) | ALDH1A1CYP2C19HIF1AFDPSLMNA | |
| SCHEMBL15229065 | 0.70 | MAOA (0.35) | ALDH1A1MAOAMAOBMEN1KMT2A | |
| SCHEMBL7179298 | 0.70 | L3MBTL1 (0.33) | MAPK1L3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL17652426 | 0.69 | IDO1 (0.38) | ALDH1A1USP2CYP2C19MAOBSMN1; SMN2 | |
| SCHEMBL6536308 | 0.68 | ALDH1A1 (0.52) | ALDH1A1MAPK1MTNR1AMTNR1BFFAR1 | |
| SCHEMBL119711 | 0.68 | TRPV6 (0.39) | ALDH1A1MAPK1CYP2C19HIF1A | |
| SCHEMBL5837659 | 0.67 | — | — | |
| SCHEMBL5838067 | 0.66 | AAK1 (0.33) | — | |
| Benzene SCHEMBL19952997 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122627-B2 | Lactam inhibitors of Hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040171556-A1 | Methods for inhibiting proteasome | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-02 | — | — | US | disclosed |
| WO-2004064755-A2 | METHODS FOR INHIBITING PROTEASOME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-05 | — | — | WO | disclosed |
| US-6586615-B1 | Boron compounds such as 1-amino-3,3-difluoropropyl boronate pinacol ester used as intermediates for antagonists of serine proteases, leukocyte elastases, cathepsins, chymotrypsin and hepatitis virus enzyme inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | disclosed |
| WO-2002054931-A2 | ALPHA-AMINOBORONIC ACIDS PREPARED BY NOVEL SYNTHETIC METHODS | BRISTOL MYERS SQUIBB COMPANY P (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-1206449-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007407-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | PRSS3, PRSS1, PREP | ALDH1A1 258/4885MAPK1 4281/4885MTNR1A 2979/4885 |
| US-20040171556-A1 | Methods for inhibiting proteasome | PSMB1, PSMB11, PSMG3 | ALDH1A1 3262/4885MAPK1 2455/4885MTNR1A 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.